# ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

> **NCT00231946** · PHASE3 · COMPLETED · sponsor: **Voyager Pharmaceutical Corporation** · enrollment: 555 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** VP4896

## Key facts

- **NCT ID:** NCT00231946
- **Lead sponsor:** Voyager Pharmaceutical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 555 (—)
- **Last updated:** 2007-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00231946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00231946, "ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00231946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*